Cellectar Biosciences to Present at the Ladenburg Thalmann 2015 Healthcare Conference
25 September 2015 - 2:30PM
Cellectar Biosciences, Inc. (NASDAQ:CLRB), an oncology-focused
biotechnology company, announces today its CEO, Jim Caruso, will be
presenting at the Ladenburg Thalmann 2015 Healthcare Conference in
New York City on September 29, 2015 at 4:00 PM ET.
"The Ladenburg Thalmann conference attracts a wide array of
emerging companies and investors alike, providing an excellent
opportunity for us to communicate our value proposition," said Mr.
Caruso. "We look forward to presenting the company and our PDC
delivery platform, which possesses the ability to link diverse
oncologic payloads for targeted delivery to a broad range of cancer
and cancer stem cell targets."
Cellectar will be presenting on September 29 at 4:00 PM ET at
the Sofitel in New York City. Following the presentation, a
link to the latest presentation deck will be posted on the
company's website.
About Cellectar Biosciences, Inc.
Cellectar Biosciences is developing phospholipid ether-drug
conjugates (PDCs) designed to provide cancer targeting delivery of
diverse oncologic payloads to a broad range of cancers and cancer
stem cells. Cellectar's PDC platform is based on the company's
proprietary phospholipid ether analogs. These novel small-molecules
have demonstrated highly selective uptake and retention in a broad
range of cancers and cancer stem cells. Cellectar's PDC pipeline
includes product candidates for cancer therapy and cancer
diagnostic imaging. The company's lead therapeutic PDC, CLR 131,
utilizes iodine-131, a cytotoxic radioisotope, as its payload. CLR
131 is currently being evaluated under an orphan drug designated
Phase I study in patients with relapsed/refractory multiple
myeloma. The company is also developing PDCs for targeted delivery
of chemotherapeutics such as paclitaxel (CLR-1601-PTX) and
gemcitabine (CLR 1605-GEM), both preclinical stage product
candidates, and plans to expand its PDC chemotherapeutic pipeline
through both in-house and collaborative R&D efforts. For
additional information please visit www.cellectar.com.
This news release contains forward-looking statements. You can
identify these statements by our use of words such as "may,"
"expect," "believe," "anticipate," "intend," "could," "estimate,"
"continue," "plans," or their negatives or cognates. These
statements are only estimates and predictions and are subject to
known and unknown risks and uncertainties that may cause actual
future experience and results to differ materially from the
statements made. These statements are based on our current beliefs
and expectations as to such future outcomes. Drug discovery and
development involve a high degree of risk. Factors that might cause
such a material difference include, among others, uncertainties
related to the ability to raise additional capital, uncertainties
related to the ability to attract and retain partners for our
technologies, the identification of lead compounds, the successful
preclinical development thereof, the completion of clinical trials,
the FDA review process and other government regulation, our
pharmaceutical collaborators' ability to successfully develop and
commercialize drug candidates, competition from other
pharmaceutical companies, product pricing and third-party
reimbursement. A complete description of risks and uncertainties
related to our business is contained in our periodic reports filed
with the Securities and Exchange Commission including our Form
10-K/A for the year ended December 31, 2014. These
forward-looking statements are made only as of the date hereof, and
we disclaim any obligation to update any such forward-looking
statements.
CONTACT: INVESTOR AND MEDIA CONTACT:
Jules Abraham
JQA Partners
917-885-7378
jabraham@jqapartners.com
Cellectar Biosciences (NASDAQ:CLRBW)
Historical Stock Chart
Von Jun 2024 bis Jul 2024
Cellectar Biosciences (NASDAQ:CLRBW)
Historical Stock Chart
Von Jul 2023 bis Jul 2024